---
title: "Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286601918.md"
description: "Goldman Sachs analyst Salveen Richter has reiterated a Buy rating on Biogen, raising the price target from $238 to $250. This decision is driven by the strong performance of Leqembi, which exceeded revenue expectations in the recent quarter. Factors supporting this outlook include a favorable revenue forecast from Eisai, anticipated catalysts for broader use of biomarkers, and potential new formulations that could enhance treatment options."
datetime: "2026-05-15T18:35:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286601918.md)
  - [en](https://longbridge.com/en/news/286601918.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286601918.md)
---

# Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Biogen, boosting the price target to $250.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Salveen Richter has given his Buy rating due to a combination of factors, primarily centered on the strong momentum of Leqembi’s launch and its outperformance versus prior expectations. The recent quarter showed Leqembi revenue ahead of both Goldman Sachs estimates and consensus, with notable strength across the U.S., Japan, and China, supporting confidence in a faster build-out of the Alzheimer’s franchise.

Richter’s view also reflects Eisai’s newly issued Leqembi revenue outlook, which aligns with or exceeds market forecasts and is underpinned by anticipated catalysts such as broader use of blood-based biomarkers, the potential approval and uptake of the IQLIK subcutaneous formulation, and future indications that could move treatment earlier in the disease course. These dynamics, combined with positive ex-U.S. opportunities and an upward revision of the BIIB price target from $238 to $250, underpin the constructive stance on Biogen shares.

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [4523.JP](https://longbridge.com/en/quote/4523.JP.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)](https://longbridge.com/en/news/286442023.md)
- [BUZZ-Street View: Skeptical on experimental Alzheimer's drug, awaits full data](https://longbridge.com/en/news/286558948.md)
- [Biogen to advance experimental Alzheimer’s drug despite mid-stage trial miss](https://longbridge.com/en/news/286407083.md)
- [Biogen Finalizes Apellis CVR Terms (Up To $4) And Secures $2 Billion Term Loan Facilities](https://longbridge.com/en/news/286417500.md)
- [Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push](https://longbridge.com/en/news/286623100.md)